Pharmacoeconomic Evaluation Of DNF-N Vs. DPF-P In The Treatment Of Locally Advanced Nasopharyngeal Carcinoma By Markov Model

Background:From the perspective of Chinese healthcare,this study compares the efficacy and adverse effects of induction chemotherapy with the DNF-N regimen(nadaplatin plus docetaxel and fluorouracil)and the DPF regimen(cisplatin plus docetaxel and fluorouracil)in locally advanced nasopharyngeal carcinoma patients,and evaluates their economic value using a Markov model based on actual patient costs.Method:Kaplan-Meier survival curves are compared to evaluate the survival benefit and adverse effects of the two regimens,and a Markov model is constructed to evaluate the cost-effectiveness of DNF-N and DPF-P in treating locally advanced nasopharyngeal carcinoma patients based on actual costs incurred by enrolled patients.One-way and probability sensitivity analyses are performed to assess the stability of the model.Results: There was no statistically significant difference in 1-year PFS rate(P=0.607,HR=1.39(95%CI 0.4-4.82))or 3-4 grade toxicity between the DNF-N and DPF-P regimens.However,the DPF-P regimen increased quality-adjusted life years by0.01237 and cost by-754.84 yuan,and the incremental cost-effectiveness ratio(ICER)was-6,1265.06 yuan,which was lower than the willingness-to-pay(WTP)threshold(257,094 yuan),indicating that the DPF-P regimen was more cost-effective in treating locally advanced nasopharyngeal carcinoma.Conclusion: In this phase Ⅲ clinical study,the DPF-P regimen was more costeffective than the DNF-N regimen in treating locally advanced nasopharyngeal carcinoma,despite no significant differences in 1-year PFS rate and grade 3-4toxicities.